Hematologic NeoplasmsNCT03023202
UWCCC Molecular Tumor Board Registry
An observational study of Hematologic Neoplasms and Solid Neoplasm, run by University of Wisconsin, Madison at 1 site in United States.
Trial summary
This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hematologic Neoplasms, Solid Neoplasm
- What is being tested?
- PMMTB (Precision Medicine Molecular Tumor Board)
- How many people
- 10,000 participants
- Where
- 1 siteUnited States
- Study dates
- 30 Mar 2016to Mar 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This study will include all patients age ≥18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor. It will require each patient to have the ability to understand and willingness to sign a written informed consent document.
Who may be able to join
- Clinically suspected or histologically confirmed solid or hematological malignancy
- Undergoing genetic testing of tumor
- Ability to understand written informed consent document
- Willingness to sign written informed consent document
Who cannot join
- Pediatric patients (age<18 years) will be excluded due to a lack of expertise on the molecular tumor committee
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792
Cancer Connect, 800-622-8922, clinicaltrials@cancer.wisc.edu
About this study
Official title: UWCCC Precision Medicine Molecular Tumor Board Registry
This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
- Conditions
- Hematologic Neoplasms, Solid Neoplasm
- Being tested
- PMMTB (Precision Medicine Molecular Tumor Board)
- Medical subject headings
- Hematologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PMMTB (Precision Medicine Molecular Tumor Board)Other
PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.
| Study group | Role | What they receive |
|---|---|---|
| PMMTB | This study of the PMMTB will include all patients >= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor.
All standard of care functions will be performed by standard procedures. Receives: Other: PMMTB (Precision Medicine Molecular Tumor Board) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Frequency of acceptance of molecular tumor board recommendations
How often the molecular tumor board's recommendations are accepted
Measured: Up to 5 years
Benefit from PMMTB recommended treatment
Whether patients benefit from PMMTB recommended treatment
Measured: Up to 5 years
Secondary outcomes (3)
Correlation of mutations with protein overexpression
Correlate mutations identified in tumor tissue with protein overexpression
Measured: Up to 5 years
Correlations of mutations with circulating tumor DNA
Correlate mutations identified in tumor tissue with circulating tumor DNA
Measured: Up to 5 years
Correlations of mutations with spheroid culture investigations
Correlate mutations identified in tumor tissue with spheroid culture investigations
Measured: Up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jan 2017 (estimated)
- Study start30 Mar 2016
- Primary completionMar 2029 (estimated)
- Study completionMar 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematologic NeoplasmsStudies of the same condition, open and under way.
- More trials run by University of Wisconsin, MadisonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 10,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Wisconsin, Madison
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Dustin Deming, MD, Principal investigator, University of Wisconsin, Madison
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03023202
- Sponsor's protocol ID
- 2015-1370
- Other IDs
- P30CA014520, 1R37CA226526-01A1, NCI-2019-06343, A533400, SMPH\UWCCC\GENERAL, Protocol Version 3/24/24, UW15068
- Status last verified
- Apr 2026
- First submitted
- 13 Jan 2017
- Last updated
- 13 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- UWCCC Precision Medicine Molecular Tumor Board Registry
- ClinicalTrials.gov ID
- NCT03023202
- Acronym / sponsor ID
- 2015-1370
- Conditions
- Hematologic Neoplasms, Solid Neoplasm
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 10,000 participants (estimated)
- Lead sponsor
- University of Wisconsin, MadisonUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 30 Mar 2016 (actual)
- Primary completion
- Mar 2029 (estimated)
- Study completion
- Mar 2029 (estimated)
- First posted
- 18 Jan 2017 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| PMMTB | – | Other: PMMTB (Precision Medicine Molecular Tumor Board)This study of the PMMTB will include all patients >= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor. All standard of care functions will be performed by standard procedures. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This study will include all patients age ≥18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor. It will require each patient to have the ability to understand and willingness to sign a written informed consent document.
Key inclusion criteria (4 listed)
- Clinically suspected or histologically confirmed solid or hematological malignancy
- Undergoing genetic testing of tumor
- Ability to understand written informed consent document
- Willingness to sign written informed consent document
Key exclusion criteria (1 listed)
- Pediatric patients (age<18 years) will be excluded due to a lack of expertise on the molecular tumor committee
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PMMTB (Precision Medicine Molecular Tumor Board)PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB. | Other | PMMTB |
Primary outcome
Frequency of acceptance of molecular tumor board recommendations
Time frame: Up to 5 years
How often the molecular tumor board's recommendations are accepted
Benefit from PMMTB recommended treatment
Time frame: Up to 5 years
Whether patients benefit from PMMTB recommended treatment
3 secondary outcomes
Correlation of mutations with protein overexpression
Time frame: Up to 5 years
Correlations of mutations with circulating tumor DNA
Time frame: Up to 5 years
Correlations of mutations with spheroid culture investigations
Time frame: Up to 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Apr 2026.
- UW Carbone Cancer Center Home PageLink provided by the sponsor.
Related trials for Hematologic Neoplasms
Not yet recruitingPhase 2
Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
RecruitingPhase 2
A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT)
Not yet recruitingPhase 1
huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
RecruitingObservational study
HPC Offered for PRESERVE Expansion
Bone Marrow Transplant (BMT)
RecruitingPhase 1
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
B-All, Acute Lymphoblastic Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Dustin Deming, MD principal investigator
University of Wisconsin, Madison
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hematologic Neoplasms and Solid Neoplasm, run by University of Wisconsin, Madison at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cancer Connect (8006228922, clinicaltrials@cancer.wisc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Frequency of acceptance of molecular tumor board recommendations (time frame: Up to 5 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2026.